News

Media releasesResearch

Tassie Devils hold clue for how human cancers evade the immune system

September 27, 2019

Melbourne researchers from Peter Mac, in collaboration with Cancer Research UK, have uncovered a new way that some human cancers can hide from the body’s immune system, a feature they share with tumours from an unlikely source - the Tasmanian devil.

General newsMedia releases

Welcoming our new Chief Executive Dr Shelley Dolan

September 23, 2019

Today we welcome Dr Shelley Dolan to Peter Mac and to Australia.

Featured servicesConferences & seminars

BOOK NOW: GAP 2020

September 20, 2019

Peter Mac is proud to host the MD Anderson Cancer Center Global Academic Program (GAP) 2020 conference for the first time in Australia.

Featured services

New Oncology Massage Service at Peter Mac

September 17, 2019

From mid-September, the Wellbeing Centre will be offering an Oncology Massage service for Peter Mac patients on Wednesdays and Fridays.

General newsClinical research & trials

Rare ovarian cancer confirmed as not seeded from elsewhere

September 6, 2019

An international study led by Peter Mac has revealed the origin of mucinous ovarian cancer (MOC) confirming, unlike other types of ovarian cancer, this rare cancer is not seeded from elsewhere in the body.

General news

Milestone as Australia’s first T-Cell therapy manufacturing license is awarded

August 29, 2019

Peter MacCallum Cancer Centre welcomes the issuing of the first license to manufacture commercial T-Cell treatments, including breakthrough CAR T-Cell therapies, within Australia. The Therapeutic Goods Administration has awarded a T-Cells GMP manufacturing licence to Cell Therapies Pty Ltd, a company which is situated at Peter Mac.

Professor Ricky Johnstone, Executive Director of Cancer Research at Peter Mac.

General newsResearchClinical research & trials

Success for Peter Mac research in latest NHMRC grant round

August 29, 2019

Groundbreaking research projects led by Peter Mac scientists and clinician researchers have attracted more than $19 million in the latest round of NHMRC grants. The funded projects include a major study of the role of vasculature in cancer progression, research into improved infection control in cancer patients, and improving the effectiveness of immunotherapies and personalised cancer treatments.

General newsMedia releasesClinical research & trials

Positive results from first-in-class, first-in-human trial of blood cancer drug

August 21, 2019

Peter Mac scientists working with the drug company Senhwa Biosciences have developed a new way to target cancer, and have demonstrated it can stall disease progression in patients who are no longer responding to conventional treatments.